New prognostic factors may be useful in staging melanoma

New prognostic factors may be useful in staging melanoma
New prognostic factors may be useful in predicting survival in patients with thin melanoma, according to research published online July 7 in the Journal of Clinical Oncology.

(HealthDay)—New prognostic factors may be useful in predicting survival in patients with thin melanoma, according to research published online July 7 in the Journal of Clinical Oncology.

Andrea Maurichi, M.D., of the Istituto Nazionale dei Tumori in Milan, and colleagues analyzed data for 2,243 patients with thin . The authors sought to explore new and construct a nomogram for predicting survival in individual patients.

The researchers found that the worst prognosis for thin melanoma was associated with age older than 60 years, Breslow thickness greater than 0.75 mm, mitotic rate (MR) of 1 or higher, presence of ulceration, presence of lymphovascular invasion (LVI), and regression of 50 percent or greater. All of these factors, except age and regression, were significantly associated with sentinel node positivity. Independent predictors of survival, including age, MR, ulceration, LVI, regression, and sentinel node status, were used to construct a nomogram for predicting overall survival at 12 years.

"Our findings suggest including LVI and regression as new prognostic factors in the melanoma staging system," the authors write. "The appears useful for risk stratification in clinical management and for recruiting patients to clinical trials."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Nonsentinel lymph nodes key factor in melanoma prognosis

Aug 02, 2013

(HealthDay)—Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

8 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

12 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.